ALNY projects product revenue growth to $4.7B-$5.1B by 2026, driven by a 25% CAGR target in TTR revenue through 2030.
Alnylam Pharmaceuticals outlined a 2026 product revenue forecast of $4.7 billion to $5.1 billion during its Q2 2026 earnings call. The company aims to sustain a 25% compound annual growth rate in TTR revenue through 2030, reflecting confidence in its pipeline and market expansion.
The projection follows a strong quarterly performance, with AMVUTTRA revenues surpassing $1 billion for the first time, equating to an annual run rate of $4 billion. This milestone underscores the drug’s growing adoption and the company’s ability to scale commercially.
Management attributed the outlook to robust demand for its RNA interference therapies and ongoing clinical advancements. The guidance aligns with prior growth trends but sets a higher long-term revenue trajectory.